Life Sciences

Fladgate LLP has advised Stonehealth Alpha Limited on its acquisition of a portfolio of health centre properties from Octopus Healthcare. The properties are spread across the UK. The acquisition marks Stonehealth’s entrance into the health sector and they plan to grow their portfolio over the next 18 months. Stonehealth were also advised by ASA Group […]

A number of Employment Tribunal and court decisions over recent years have examined the effect of suspending an employee in order to investigate disciplinary allegations.  The result is that suspension, which might once have been considered a neutral act necessary to allow an unimpeded investigation and/or to prevent a recurrence of acts of misconduct, has now […]

João Andrade, CEO of Widecells, discusses the company’s ambitious growth plans in Biotech & Money – we’re delighted that he’s referenced the contribution made by Fladgate LLP and partner Paul Airley. Please see below for link to article. WideCells sets course for synergistic growth  

Fladgate has advised WideCells Group PLC, the healthcare services provider to the stem cell industry, on its recent placing to raise gross funds of approximately £750,000.  The proceeds will be used to accelerate the roll out of its three stem cell services divisions, CellPlan (the group’s stem cell insurance product), WideCells (the group’s stem cell storage […]

Fladgate LLP is delighted to have achieved across the board rankings in the recently launched 2017 edition of the Legal 500 Guide to the UK Legal Profession. The firm achieved 26 rankings, with 59 lawyers attaining 91 individual recommendations.  Commercial contracts Fladgate LLP enhanced its commercial contracts offering with the recruitment of James Earl, an expert in the […]

Fladgate has advised WideCells Group PLC, the healthcare services provider to the stem cell industry, on their recent placing to raise gross funds of approximately £650,000.  The proceeds will be used to take advantage of a number of identified opportunities to accelerate the roll out of its three stem cell services divisions, CellPlan, WideCells and […]

Fladgate LLP is delighted to have achieved across the board rankings in the recently launched 2016 edition of the Legal 500 Guide to the UK Legal Profession. The firm achieved 27 rankings with a further 57 individual recommendations. Commercial contracts Eddie Powell led the advice to MLCG on the negotiation of a multi-year exclusive supply agreement with […]

Fladgate LLP has advised WideCells Group PLC, the health care services provider to the growing stem cell industry, on its entry to the Main Market of the London Stock Exchange, by way of a Standard listing on the Official List of the UKLA, following a successful £2m placing organised by Vicarage Capital Ltd and Shard […]

Fladgate is delighted to have achieved a Top 10 ranking in the January edition of the ARL AIM Advisers Rankings Guide. Editorial commentary states: “Perhaps the most noteworthy move through the quarter was attributable to Fladgate.  The law firm moved up 10 places into a share of eighth… after it appointed two partners and an […]

Fladgate is delighted to announce the appointment of corporate partners Nigel Gordon and Chris Chrysanthou, who join from Fasken Martineau LLP, together with senior associate Zehra Kofturcu. It is anticipated that the incoming practice of the team will add significantly to Fladgate’s already extensive M&A and AIM practice, taking the firm into the top 10 […]

IP owners continue to get punishment dished out to them, and not on a consensual basis. A recent decision of the UK’s Court of Appeal has reviewed the rules that dictate when parallel (or “grey”) market product can be rebranded to match the brand used by the market leader in the national market concerned. The […]

Fladgate LLP advised management on the sale to the founders of the shares of IPS Specials, a company backed by private equity house, Elysian Capital. IPS Specials produces customised ‘specials’, which are unlicensed drugs prescribed by doctors to patients with rare conditions or who cannot take licensed drugs for reasons such as allergies. Fladgate corporate […]